Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Secukinumab 300 mg, s.c.
BIOLOGICAL
2 trials
Sponsors
Novartis Pharmaceuticals
Conditions
Giant Cell Arteritis
Phase 2
A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
Completed
NCT03765788
Novartis Pharmaceuticals
Giant Cell Arteritis
Start: 2019-01-30
End: 2021-06-08
Updated: 2023-08-21
Phase 3
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
Completed
NCT05380453
Novartis Pharmaceuticals
Giant Cell Arteritis
Start: 2022-09-29
End: 2026-02-24
Updated: 2026-02-27
Related Papers
Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.
2023-06-01
41 citations
Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial.
2021-08-17
26 citations